QuidelOrtho (NASDAQ:QDEL) Posts Earnings Results, Beats Estimates By $0.13 EPS

QuidelOrtho (NASDAQ:QDEL) released its quarterly earnings results on Tuesday. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.13, FiscalAI reports. The company had revenue of $618.90 million for the quarter, compared to analyst estimates of $627.83 million. QuidelOrtho had a positive return on equity of 4.88% and a negative net margin of 39.20%. The firm’s revenue was down 11.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.80 earnings per share.

Here are the key takeaways from QuidelOrtho’s conference call:

• China and respiratory weakness drove the decline: Q3 revenue fell 12% to $619 million, with China down 45% and Point of Care down 27% as respiratory revenue declined 39%. Management expects China to fall from about 8% of revenue in 2026 to 4%–5% in 2027 amid destocking, pricing pressure, and competition.
• Core businesses continued to grow outside China: Labs revenue rose 4% and immunohematology revenue rose 3%, supported by demand across key markets and the company’s installed base.
• A new restructuring program targets more than $80 million in annual savings in 2027, which management says should more than offset near-term China headwinds. The program will incur $30 million–$35 million in restructuring charges, with most of the cash outflow expected in Q4 2026.
• Guidance and leverage reflect continued pressure: The company narrowed 2026 revenue guidance to $2.52 billion–$2.54 billion and expects adjusted EBITDA of $540 million–$545 million and adjusted EPS of $0.65–$0.70. Free cash flow was approximately break-even in Q3, while net leverage rose to 4.5x from 4.3x in Q2.

QuidelOrtho Trading Up 0.4%

Shares of NASDAQ:QDEL opened at $14.09 on Wednesday. The stock has a 50 day moving average of $12.74 and a 200 day moving average of $16.27. The company has a market cap of $966.15 million, a PE ratio of 10.39 and a beta of 0.77. The company has a current ratio of 1.39, a quick ratio of 0.76 and a debt-to-equity ratio of 1.43. QuidelOrtho has a 12-month low of $9.92 and a 12-month high of $35.58.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Citigroup lifted their price target on shares of QuidelOrtho from $13.00 to $18.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Weiss Ratings restated a “sell (e+)” rating on shares of QuidelOrtho in a research report on Thursday, October 15th. Finally, Zacks Research upgraded shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a report on Friday, October 9th. Four analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus price target of $13.62.

More QuidelOrtho News

Here are the key news stories impacting QuidelOrtho this week:

• Positive Sentiment: The company launched a cost transformation and restructuring program expected to generate more than $80 million in annual savings in 2027. Management also cited growth in Labs and Immunohematology businesses outside China as signs of underlying strength. QuidelOrtho Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: QuidelOrtho narrowed its full-year 2026 guidance ranges and announced business leadership changes; the available reports did not specify the revised guidance figures or detailed implications of the leadership shifts. QuidelOrtho Announces Restructuring and New Business Leadership Changes
• Negative Sentiment: Revenue was $618.9 million, down about 12% year over year and below the cited analyst consensus of $627.8 million. EPS of $0.31 beat the $0.18 consensus, but was well below $0.80 a year earlier, highlighting continued deterioration in results. QuidelOrtho reports sales below analyst estimates in Q3 2026 earnings

QuidelOrtho Company Profile

QuidelOrtho Corporation (NASDAQ:QDEL) is a global in vitro diagnostics company formed through the combination of Quidel Corporation and Ortho Clinical Diagnostics, a transaction completed in 2022. The company develops, manufactures and markets diagnostic technologies used to detect disease, guide treatment decisions and support blood-transfusion safety.

Its portfolio includes rapid immunoassays, molecular testing systems, clinical chemistry and immunohematology products, as well as laboratory automation solutions.